PharmPK Discussion - LC MS/MS analysis: K3EDTA vs. K2EDTA

• On 16 Nov 2011 at 14:19:40, Jennifer Norman (Jennifer.Norman.at.uct.ac.za) sent the message
  

  
  Can anyone provide me with a reference providing support for either the
  K2 or the K3 counterion when sampling with EDTA in analytical studies?
  
  Many thanks,
  Jennifer
  
  Jennifer Norman MRQA
  BSc (MED) Hons Pharmacology MSc
  QA and Logistics Manager
  UCT Pharmacology Laboratory
  Division of Clinical Pharmacology
  
  

  Back to the Top

• On 16 Nov 2011 at 11:21:08, (Ttarnowski1.at.aol.com) sent the message
  

  
  Jennifer-
  I believe that the 2007 J Pharm Sci White Paper Article from the 2006
  Crystal City Conference indicated that the general feeling was that the
  counterion for EDTA was not generally a critical factor.  I'm traveling
  today, so can't provide the exact citation.
  
  -Tom
  
  Thomas Tarnowski, Ph D.
  Director, CMC and Bioanalytics
  Elan Pharmaceuticals
  South San Francisco, CA
  
  

  Back to the Top

• On 16 Nov 2011 at 12:23:24, deanknuth (deanknuth.aaa.jasperclinic.biz) sent the message
  

  
  The following message was posted to: PharmPK
  
  The reference Tom mentions is
  http://www.aapsj.org/articles/aapsj0901/aapsj0901004/aapsj0901004.pdf
  
  Page E39 carries the discussion; no consensus was reached on this point.
  
  dean
  
  Dean W. Knuth
  President & CEO
  Jasper Clinical Research & Development, Inc.
  526 Jasper Street
  Kalamazoo MI 49007
  
  

  Back to the Top

• On 17 Nov 2011 at 09:03:04, Alvaro Ganza/FAES (aganza.-a-.faes.es) sent the message
  

  
  Another more recent reference:
  http://www.future-science.com/doi/full/10.4155/bio.11.240
  
  Best Regards
  --
  
  Another article in the same number:
  http://www.future-science.com/doi/abs/10.4155/bio.11.239
  Best Regards
  
  

  Back to the Top

Copyright 1995-2011 David W. A. Bourne (david@boomer.org)